February 09, 2021
1 min read

Vyzulta approved in South Korea

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The Ministry of Food and Drug Safety in South Korea has granted regulatory approval for Vyzulta, according to a press release from Bausch Health.

The latanoprostene bunod ophthalmic solution 0.024% is indicated to reduce IOP in patients with open-angle glaucoma and ocular hypertension.

"Vyzulta is an important treatment option for people suffering from glaucoma, and we are committed to securing additional regulatory approvals for Vyzulta in countries around the world," Thomas J. Appio, president of Bausch + Lomb/International, said in the release.

Vyzulta is also approved in the United States, Canada, Hong Kong, Mexico, Taiwan, Argentina, Colombia and Ukraine.